RINVOQ is an oral selective and reversible JAK inhibitor indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monothrrapy or in combination with methotrexate.
Starting patients on RINVOQ: Helpful information
This convenient guide helps educate you on starting patients on RINVOQ, with information on dosing plus screening, monitoring, and safety recommendations.
RINVOQ HCP Educational Brochure
[Affiliate to insert link to localized version of HCP Educational Brochure from RMP from PV]
Support for your patients, every step of the way
Personalized support services, tailored to your patients' needs
We offer a range of services for your patients to help support them.
Find out more about patient support services.
TITLE OF EVENT
Subhead
Date | Location
[Affiliates to insert congresses and meetings as approved by local guidance.]
TITLE OF EVENT
Subhead
Date | Location
[Affiliates to insert congresses and meetings as approved by local guidance.]
I want to receive more information via a product specialist.
I have a question for Medical Information.